FastWave Medical Closes Series Pre-A Financing

FastWave Medical has recently closed their Series Pre-A financing round, following its recent acquisition by China Grand Pharmaceutical and Healthcare Holdings.

Minneapolis-based FastWave Medical is a biomedical company focused on developing novel intravascular devices that are safe, efficacious, and cost-effective.They have announced that these funds will be directed towards advancing their research and development and to achieve key regulatory initiatives for its endovascular therapies to treat calcific artery disease.

The acquisition by China Grand Pharmaceutical was previously announced on August 2. China Grand Pharmaceutical will acquire 100% equity of FastWave Medical with up to a total of $72 million by phases and will invest up to total $8 million for supporting and jointly developing an intravascular shockwave calcification treatment system.

The acquisition, along with the funding, will be contingent on FastWave Medical’s progress and completion of key technical, clinical and regulatory milestones.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts